1921
Volume 83, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

In 2004, Sudan adopted artesunate + sulfadoxine/pyrimethamine (SP) combination as the first-line drug, in response to the high level of resistance to antimalarials. In 2007, a molecular study on antimalarial resistance linked genes, , , , , and , was conducted on 198 isolates from central and eastern Sudan. We observed a high frequency of point mutations at almost all loci analyzed, mainly of 76T (72.7%), 51I (75.3%), and 108N (72.7%) alleles. The MARK III test for chloroquine sensitivity in 45 isolates showed that 37.8% of the isolates were low resistant and 6.7% were fully resistant. This study represents the most recent molecular investigation on antimalarial resistance in this area after the adoption of artemisinin-based combination therapy (ACT), and underlines the importance of the analysis of SP resistance evolution to monitor the efficacy of ACT therapy in endemic areas.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.09-0514
2010-08-05
2017-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/2/250.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0514&mimeType=html&fmt=ahah

References

  1. Wellems T, Plowe C, , 2001. Chloroquine-resistant malaria. J Infect Dis 184: 770776.[Crossref]
  2. White NJ, , 2004. Antimalarial drug resistance. J Clin Invest 113: 10841092.[Crossref]
  3. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR, , 2002. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2: 209218.[Crossref]
  4. Hayton K, Su XZ, , 2004. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr Drug Targets Infect Disord 4: 110.[Crossref]
  5. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Björkman A, Gil JP, , 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191: 10141017.[Crossref]
  6. Basco LK, Tahar R, Ringwald P, , 1998. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites. Antimicrob Agents Chemother 42: 18111844.
  7. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, , 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum . Proc Natl Acad Sci USA 85: 91099113.[Crossref]
  8. de Pecoulas PE, Basco LK, Le Bras J, Mazabraud A, , 1996. Association between antifol resistance in vitro and DHFR gene point mutation in Plasmodium falciparum isolates. Trans R Soc Trop Med Hyg 90: 181182.[Crossref]
  9. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE, , 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565568.
  10. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, , 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17: 582588.[Crossref]
  11. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, , 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380388.[Crossref]
  12. Mberu EK, Mosobo MK, Nzila AM, Kokwaro GO, Sibley CH, Watkins WM, , 2000. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am J Trop Med Hyg 62: 396401.
  13. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, , 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother 44: 991996.[Crossref]
  14. Balint GA, , 2001. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther 90: 261265.[Crossref]
  15. World Health Organization, 2001. Antimalarial Drug Combination Therapy. Geneva: World Health Organization, WHO/CDS/RBM/2001.35.
  16. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, , 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 26192620.[Crossref]
  17. Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala MT, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O, , 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366: 19601963.[Crossref]
  18. Legrand E, Volney B, Meynard JB, Esterre P, Mercereau-Puijalon O, , 2007. Resistance to dihydroartemisinin. Emerg Infect Dis 13: 808809.[Crossref]
  19. Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, East M, Lee A, Brady L, Haynes RK, Krishna S, , 2005. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 12: 628629.[Crossref]
  20. Eckstein-Ludwig U, Webb RJ, van Goethem IDA, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S, , 2003. Artemisinins target the SERCA of Plasmodium falciparum . Nature 424: 957961.[Crossref]
  21. Sudan, Country Profile. Available at: http://rbm.who.int/wmr2005/profiles/sudan.pdf. Accessed April 28, 2005.
  22. Malik EM, Nour SM, Hamid IK, Elmardi KA, Mohamed TA, Ahmed ES, , 2005. From home to hospital: beliefs and practices related to severe malaria in Sudan. J Family Community Medicine 12: 8590.
  23. Yousif MA, Adeel AA, , 2000. Antimalarials prescribing pattern in Gazera State: precepts and practices. East Mediterr Health J 6: 939947.
  24. Omer AH, , 1978. Response of Plasmodium falciparum in Sudan to oral chloroquine. Am J Trop Med Hyg 27: 853857.
  25. Kouznetsov RL, Rooney W, Wernsdorfer WH, El Gaddal AA, Payne D, Abdalla RE, , 1980. Use of the in vitro microtechnique for the assessment of drug sensitivity of Plasmodium falciparum in Sennar, Sudan. Bull World Health Organ 58: 785789.
  26. Ibrahim AM, Ali FR, Ali ME, , 1992. Assessment of chloroquine resistance of Plasmodium falciparum in children of Wad Medani (central Sudan). J Trop Pediatr 38: 162166.[Crossref]
  27. Nour BY, Faragalla IA, Saeed OK, Mohamadani AA, , 2006. In vitro study assessing the response of Plasmodium falciparum malaria to chloroquine, sulfadoxine/pyrimethamine, quinine and mefloquine in Wad Medani District, Sudan. Saudi Med J 27: 808812.
  28. Bayoumi RA, Babiker HA, Ibrahim SM, Ghalib HW, Saeed BO, Khider S, Elwasila M, Karim EA, , 1989. Chloroquine resistant Plasmodium falciparum in Eastern Sudan. Acta Trop 461: 157165.[Crossref]
  29. Babiker HA, Satti G, Ferguson H, Bayoumi R, Walliker D, , 2005. Drug resistant Plasmodium falciparum in an area of seasonal transmission. Acta Trop 94: 260268.[Crossref]
  30. Ibrahim ME, Awad-el-Kariem FM, el Hassan IM, el Mubarak ER, , 1991. A case of Plasmodium falciparum malaria sensitive to chloroquine but resistant to pyrimethamine/sulfadoxine in Sennar, Sudan. Trans R Soc Trop Med Hyg 85: 446.[Crossref]
  31. A-Elbasit IE, Khalil IF, Elbashir MI, Masuadi EM, Bygbjerg IC, Alifrangis M, Giha HA, , 2008. High frequency of Plasmodium falciparum CICNI/SGEAA and CVIET haplotypes without association with resistance to sulfadoxine/pyrimethamine and chloroquine combination in the Daraweesh area, in Sudan. Eur J Clin Microbiol Infect Dis 27: 725732.[Crossref]
  32. A-Elbasit IE, Elbashir MI, Khalil IF, Alifrangis M, Giha HA, , 2006. The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural eastern Sudan: the interrelation between resistance, age and gametocytogenesis. Trop Med Int Health 11: 604612.[Crossref]
  33. Alifrangis M, Enosse S, Khalil IF, Tarimo DS, Lemnge MM, Thompson R, Bygbjerg IC, Rønn AM, , 2003. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. Am J Trop Med Hyg 69: 601606.
  34. Anderson TJ, Nair S, Jacobzone C, Zavai A, Balkan S, , 2003. Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan. Trop Med Int Health 8: 10681073.[Crossref]
  35. National Malaria Control Program, 2004. The National Protocol for Treatment of Malaria. Khartoum, Sudan: Federal Ministry of Health.
  36. Alker AP, Mwapasa V, Meshnick SR, , 2004. Rapid real-time PCR genotyping of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium falciparum . Antimicrob Agents Chemother 48: 29242929.[Crossref]
  37. Wilson PE, Kazadi W, Kamwendo DD, Mwapasa V, Purfield A, Meshnick SR, , 2005. Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. Acta Trop 93: 97106.[Crossref]
  38. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, , 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol 108: 1323.[Crossref]
  39. Duraisingh MT, Curtis J, Warhurst DC, , 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 89: 18.[Crossref]
  40. Menegon M, Sannella AR, Majori G, Severini C, , 2008. Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins. Parasitol Int 57: 233235.[Crossref]
  41. World Health Organization, 2001. In vitro Micro-Test (MARK III) for the Assessment of the Response of Plasmodium falciparum to Chloroquine, Mefloquine, Quinine, Amodiaquine, Sulfadoxine/Pyrimethamine and Artemisinin. WHO/MAL/97.20.
  42. Malik EM, Mohamed TA, Elmardi KA, Mowien RM, Elhassan AH, Elamin SB, Mannan AA, Ahmed ES, , 2006. From chloroquine to artemisinin-based combination therapy: the Sudanese experience. Malar J 5: 65.[Crossref]
  43. Osman ME, Mockenhaupt FP, Bienzle U, Elbashir MI, Giha HA, , 2007. Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fitness cost of multiple mutations in P. falciparum . Infect Genet Evol 7: 5259.[Crossref]
  44. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D, , 2001. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance gene pfmdr1 . J Infect Dis 183: 15351538.[Crossref]
  45. Borrmann S, Binder RK, Adegnika AA, Missinou MA, Issifou S, Ramharter M, Wernsdorfer WH, Kremsner PG, , 2002. Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo . Trans R Soc Trop Med Hyg 96: 660663.[Crossref]
  46. Noedl H, Wongsrichanalai C, Wernsdorfer WH, , 2003. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol 19: 175181.[Crossref]
  47. Daily JP, Roberts C, Thomas SM, Ndir O, Dieng T, Mboup S, Wirth DF, , 2003. Prevalence of Plasmodium falciparum pfcrt polymorphisms and in vitro chloroquine sensitivity in Senegal. Parasitology 126: 401405.[Crossref]
  48. Thomas SM, Ndir O, Dieng T, Mboup S, Wypij D, Maguire JH, Wirth DF, , 2002. In vitro chloroquine susceptibility and PCR analysis of pfcrt and pfmdr1 polymorphisms in Plasmodium falciparum isolates from Senegal. Am J Trop Med Hyg 66: 474480.
  49. Chen N, Russell B, Fowler E, Peters J, Cheng Q, , 2002. Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcrt and pfmdr1 . J Infect Dis 185: 405407.[Crossref]
  50. Laufer MK, Plowe CV, , 2004. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Updat 7: 279288.[Crossref]
  51. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, , 2006. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med 355: 19591966.[Crossref]
  52. Tahar R, Ringwald P, Basco LK, , 2009. Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene. Am J Trop Med Hyg 81: 1318.
  53. Dahlström S, Veiga MI, Ferreira P, Mårtensson A, Kaneko A, Andersson B, Björkman A, Gil JP, , 2008. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Infect Genet Evol 8: 340345.[Crossref]
  54. A-Elbasit IE, Alifrangis M, Khalil IF, Bygbjerg IC, Masuadi EM, Elbashir MI, Giha HA, , 2007. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics. Malar J 6: 108.[Crossref]
  55. Mockenhaupt FP, Bousema JT, Eggelte TA, Ehrhardt S, Otchwemah RN, Sauerwein RW, Bienzle U, , 2005. Concurrence of Plasmodium falciparum dhfr and crt mutations in northern Ghana. Malar J 4: 42.[Crossref]
  56. Mockenhaupt FP, Eggelte TA, Till H, Bienzle U, , 2001. Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana. Trop Med Int Health 6: 749755.[Crossref]
  57. Toteja R, Nair L, Bhasin V, , 2001. Genome comparison of progressively drug resistant Plasmodium falciparum lines derived from drug sensitive clone. Mem Inst Oswaldo Cruz 96: 427433.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0514
Loading
/content/journals/10.4269/ajtmh.2010.09-0514
Loading

Data & Media loading...

  • Received : 02 Sep 2009
  • Accepted : 26 Apr 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error